"Immune Therapeutics Joins Investor Relations Partners to Expand Company's Strategic Investor Relations Program"

"ORLANDO, Fla., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Investor Relations Partners (IRP), one of the fastest growing investor and public relations firms in the nation, today announced that Immune Therapeutics Inc. (OTCQB:IMUN), a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer, has retained IRP to expand the Company’s strategic investor relations program.

“Immune Therapeutics achieved a number of milestones in 2016 that set the groundwork for what should be the single most important year for the Company since its inception,” said Noreen Griffith, Chief Executive Officer of Immune Therapeutics, Inc. “This year’s goals will include reaching a number of significant milestones for the Company, including but not limited to, launching into full commercialization, growing revenues at a rate fast enough to enable us to achieve profitability and of course expanding our product lines both within existing and new customers.  We have retained IRP to help communicate the series of expected positive developments to the investment community in an effort to significantly increase our exposure as well as support our overriding goal of building shareholder value,” concluded Ms. Griffith.

To be added to the Company’s investor lists, please contact Kevin Yamano at Investor Relations Partners at 818-280-6800 or via email at kyamano@irpartnersinc.com. 

About Investor Relations Partners

Investor Relations Partners, Inc. (IRP) is a full-service investor relations firm serving a global client base.  The principals of IRP have received top industry awards for their investor relations programs for a number of high-profile companies, including, but not limited to, Starwood Hotels & Resorts Worldwide, ValueVision Media, Taro Pharmaceuticals, and LJ International. The firm’s principals have executed effective investor relations programs for dozens of public companies, ranging from emerging micro-cap companies to multinational corporations with market capitalizations in excess of $15 billion.  For further information on IRP, please visit the firm’s Website at www.irpartnersinc.com."

https://globenewswire.com/news-release/2017/01/26/911254/0/en/Immune-Therapeutics-Retains-Investor-Relations-Partners-to-Support-Company-s-Strategic-IR-Program-as-it-Prepares-for-Commercialziation.html